Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Novo nordisk | Vintage Vibes

Two Drugmakers Paid More Than a Quarter Million American Prescribers as Weight Loss Drug Sales Climbed

An analysis of federal payment data found Eli Lilly and Novo Nordisk paid over 250,000 US prescribers as GLP-1 weight loss drug sales grew.

Medical Daily

Can a New Weight Loss Treatment Escape the Legal and Regulatory Thicket?

It’s Eli Lilly vs. RFK Jr. in a battle over the rules around retatrutide.

Reason

Novo Nordisk Halts Two More Heart Failure Trials of Ziltivekimab After a Data Committee Found Futility

Novo Nordisk stopped the HERMES and ATHENA heart failure trials of ziltivekimab for futility, ending study treatment for enrolled patients.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Weight-loss pill "Wegovy" available in German pharmacies from 1 September

The weight-loss pill Wegovy is now available in German pharmacies. Its active ingredient semaglutide increases satiety and the adult dose costs 170 to 280 euros.

Euronews

Philadelphia Cycling Classic men: Tim Torn Teutenberg sprints to first pro victory from late breakaway

Ronald Donaldson is second and Jonas Rutsch takes third in revived American race

Cycling News

Eli Lilly’s Mounjaro wins FDA approval for a major new cardiovascular benefit

Eli Lilly's Mounjaro received FDA approval for reducing heart attack and stroke risks. This new indication expands its use beyond diabetes and weight management. The drug demonstrated an 8% greater reduction in cardiovascular events in a key study. Mounjaro's approval strengthens Eli Lilly's position in the GLP-1 medicine market. This…

The Economic Times

'Game-changer' GLP-1s could fix America's obesity crisis—but 2 inequalities stand in the way

Wells Fargo Industry Insights' Robin Wenzel says the drugs are rewriting healthcare economics, but the math doesn't "pencil out" too often.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Prescription Drug Prices Fell 3.1 Percent Over the Year, but That Number Measures Less Than You Think

Prescription drug prices posted their steepest annual drop since 1963. Here is what the index actually measures and what it leaves out.

Medical Daily

Waist Size Flags Heart Risk in Adults Whose BMI Looks Normal, Large Pooled Analysis Finds

A pooled analysis of 259,388 adults found waist measures flagged elevated heart risk in many people whose BMI looked entirely normal.

Medical Daily

Czech Tour: Riley Sheehan squeezes past Ben Turner to win tight stage 1 sprint

US rider takes first leader's jersey of four-day stage race

Cycling News

Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetes

Britain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the UK. Foundayo will launch privately later this month via prescription. Novo Nordisk's Wegovy pill also received approval for the UK market. The weight-loss drug market is seeing increased…

The Economic Times

A Major Anti-Inflammatory Heart Drug Trial Failed, Testing a Leading Theory About Artery Disease

Novo Nordisk's ziltivekimab lowered inflammation but did not reduce heart attacks, strokes, or cardiovascular deaths in a 6,300-patient trial.

Medical Daily

Weight loss drug Wegovy made Novo Nordisk Europe’s most valuable company. Finding its next blockbuster drug is proving difficult

A clinical trial failure and U.S. competition have been tough for the Danish pharmaceutical firm. CFO Karsten Munk Knudsen says the company is doubling down on innovation and its weight loss pills as it looks toward its next stage of growth.

Fortune

Bank of America CEO Says The Company Spends $250 Million A Year on GLP-1 Drugs for Their Employees. He Calls It a Good Investment

Bank of America CEO Brian Moynihan said the company has dramatically increased its investment in medications such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound.

International Business Times

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic

Hims & Hers Health shares have rallied despite an FTC lawsuit over data sharing and billing practices, as weight-loss drug partnerships and Wall Street's cautious Hold rating shape the stock's outlook ahead of Q2 earnings.

The Economic Times

Global Market: European shares climb as earnings, US-Iran diplomacy lift sentiment

European stocks advanced on Wednesday, driven by U.S.-Iran diplomatic talks. Mining companies led the rally as geopolitical concerns eased for investors. Novo Nordisk shares fell despite an improved outlook due to drug trial setbacks. Sandoz surged on strong second-quarter net sales, boosting healthcare stocks. Siemens Energy also gained following record…

The Economic Times

Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipeline

Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline after recent trial setbacks. The company raised its 2026 sales and profit outlook, but shares fell as investors focused on weaker-than-expected Wegovy pill sales and another setback for obesity…

International Business Times

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb

U.S.-listed shares of Novo Nordisk fell more than 6% after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

Novo Nordisk A/S (NYSE:NVO) stock is trading lower on Tuesday despite the company raising its fiscal 2026 guidance.

Cycling News

Tour of Denmark: Wout van Aert seals overall victory as Rasmus Søjberg Pedersen wins crash-marred stage 5 sprint

Visma-Lease a Bike rider takes second overall title in Danish stage race after 2018 victory

Barchart

NVO Stock Plummets as Novo Nordisk Heart Drug Fails Late-Stage Trial

Novo Nordisk stock is sinking on a disappointing Phase 3 clinical trial. Here’s how you should play NVO shares following the dip.

Cycling News

Tour of Denmark: Wout van Aert scores hat-trick on stage 3 with a win on wet and wild queen stage

Lukaš Kubiš retains second place on GC with runner-up finish to race leader

Medical Daily

New Research Finds Semaglutide Users Held Lower Calorie Intake For More Than A Year

A 60-week Penn trial found semaglutide users ate 24% to 30% fewer calories than placebo, even after appetite suppression faded. Here is the detail.

The Economic Times

Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers about treatment comparisons. Lilly denies wrongdoing and stands by its advertising claims. Both companies compete in the growing obesity and diabetes drug market. Novo Nordisk argues Lilly uses outdated…

The Independent UK

Two weight-loss drugmakers in legal battle over which is most effective in helping users shed pounds

Novo Nordisk claims Eli Lilly compared peak doses of Zepbound against outdated, lower doses of Wegovy to advertise a 50-pound weight loss versus 33 pounds

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Red BullBoraHansgrohe

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.